SEARCH

SEARCH BY CITATION

References

  • 1
    Spechler SJ & Goyal RK. Barrett's esophagus. N Engl J Med 1986; 315: 362 71.
  • 2
    Pera M, Cameron AJ, Trastek VJ, et al. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology 1993; 104: 510 3.
  • 3
    Devesa SS, Blot WJ, Fraumeni JF. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998; 83: 2049 53.DOI: 10.1002/(sici)1097-0142(19981115)83:10<2049::aid-cncr1>3.3.co;2-u
  • 4
    Sampliner RE, Hixson LJ, Fennerty MB, Garewal HS. Regression of Barrett's esophagus by laser ablation in an acid environment. Dig Dis Sci 1993; 38: 365 8.
  • 5
    Berenson MM, Johnson TD, Markowitz NR, et al. Restoration of squamous mucosa after ablation of Barrett's esophagus epithelium. Gastroenterology 1993; 104: 1686 91.
  • 6
    Jones R, Barnham CP, Hardwick R, Shepherd N, et al. Regression of columnar-lined esophagus following KTP laser ablation with acid suppression. Gastroenterology 1996; 110: A537A537(Abstract).
  • 7
    Laukka MA & Wang KK. Initial results using low dose photodynamic therapy in the treatment of Barrett's esophagus. Gastrointest Endosc 1994; 42: 59 63.
  • 8
    Wang KK, Geller A, Gutta K, Laukka M, et al. Photodynamic therapy in the treatment of Barrett's esophagus. Gastroenterology 1996; 110: A290A290(Abstract).
  • 9
    Overholt B, Panjehpour M, Tefftellar E, Rose M. Photodynamic therapy for treatment of early adenocarcinoma in Barrett's esophagus. Gastrointest Endosc 1993; 39: 73 6.
  • 10
    Overholt BF & Panhehpour M. Barrett's esophagus: photodynamic therapy for ablation of dysplasia, reduction of specialized mucosa, and treatment of superficial esophageal cancer. Gastrointest Endosc 1995; 42: 64 70.
  • 11
    Overholt BF & Pannehpour M. Photodynamic therapy for Barrett's esophagus: clinical update. Am J Gastroenterol 1996; 91: 1719 23.
  • 12
    Barr H, Shepherd NA, Roberts DJH, Tan WC, et al. Eradication of high grade dysplasia in columnar lined (Barrett’s) oesopha- gus by photodynamic therapy with endogenously generated protoporphyrin IX. Lancet 1996; 348: 584 5.DOI: 10.1016/s0140-6736(96)03054-1
  • 13
    Sampliner RE, Fennerty MB, Garewal HS. Reversal of Barrett's esophagus with acid suppression and multipolar electrocoa- gulation: preliminary results. Gastrointest Endosc 1996; 44: 523 5.
  • 14
    Aronchick CA, Lipshutz WH, Wright SH, DuFrayne FJ, et al. P9 bicap cautery converts Barrett's epithelium to squamous mucosa. Am J Gastroenterol 1995; 90: 15541554(3).
  • 15
    Fass R, Yalam JM, Camargo L, Johnson C, Garewal HS, Sampliner RE. Increased esophageal chemoreceptor sensitivity to acid in patients after successful reversal of Barrett's esophagus. Dig Dis Sci 1997; 42: 1853 8.
  • 16
    Mulholland MW, Reid BJ, Levine DA, Rubin CE. Elevated gastric acid secretion in patients with Barrett's metaplastic epithelium. Dig Dis Sci 1989; 34: 1329 35.
  • 17
    Collen MJ, Lewis JH, Benjamin SB. Gastric acid hypersecretion in refractory gastroesophageal reflux disease. Gastroenterology 1990; 98: 654 61.
  • 18
    Collen MJ & Johnson DA. Correlation between basal acid output and daily ranitidine dose required for therapy in Barrett's esophagus. Dig Dis Sci 1992; 37: 570 6.
  • 19
    Hirschowitz BI. Gastric acid and pepsin secretion in patients with Barrett's esophagus and appropriate controls. Dig Dis Sci 1996; 41: 1384 91.
  • 20
    Brandt L & Kaubar D. Laser-induced transient regression of Barrett's epithelium. Gastrointest Endosc 1992; 38: 619 22.
  • 21
    Brandt L, Blansky A, Kauvar D. Repeat laser therapy of recurrent Barrett's esophagus: success with anacidity. Gastrointest Endosc 1994; 3: 267.
  • 22
    Byrne J, Armstrong G, Attwood S. Restoration of the normal squamous lining in Barrett's esophagus by argon beam plasma coagulation. Am J Gastroenterol 1998; 93: 1810 5.
    Direct Link:
  • 23
    Jackson F, Husson M, Wright S, Lipschutz W, DuFrayne F, Aronchick C. Eradication of Barrett's epithelium with multipolar electrocoagulation. Gastrointest Endosc 1997; 45: AB71 187.
  • 24
    Kovacs B, Chen Y, Lewis T, DeGuzman L, Thompson K. Successful reversal of Barrett's esophagus with multipolar electrocoagulation despite inadequate acid suppression. Gastrointest Endosc 1999; 9: 547 53.
  • 25
    VanLaethem JL, Cremer M, Peny MO, Delhaye M, Deviere J. Eradication of Barrett's mucosa with argon plasma coagulation and acid suppression: immediate and mid term results. Gut 1998; 43: 747 51.
  • 26
    Sampliner RE. Ablative therapies for the columnar lined esophagus. Gastroenterol Clinics N Am 1997; 26: 685 93.
  • 27
    Schulz H, Miehlke S, Antos D, et al. Ablation of Barrett's epithelium by endoscopic argon plasma coagulation used in combination with high dose omeprazole. Gastroenterology 1999; 116: G1339G1339.
  • 28
    Sampliner RE. Practice parameters committee of the ACG. Practice guidelines on the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol 1998; 93: 1028 32.
    Direct Link:
  • 29
    Weiner GJ & Morgan TM. Ambulatory 24-hour esophageal pH monitoring, reproducibility and variability of pH parameters. Dig Dis Sci 1988; 33: 1127 33.
  • 30
    Sharma P, Sampliner RE, Camargo E. Normalization of esophageal pH with high dose proton pump inhibitor therapy does not result in regression of Barrett's esophagus. Am J Gastroenterol 1997; 92: 582 5.
  • 32
    Just R, Gideon RM, Castell DO. Omeprazole resistance in patients with gastroesophageal reflux. Gastroenterology 1994; 106: A101A101(Abstract).
  • 33
    Gupta PK, Flockhart N, Soukhova N, et al. Omeprazole metabolism in patients with refractory gastroesophageal reflux (GER). Gastroenterology 1994; 106: A84A84(Abstract).
  • 34
    Leite LP, Johnston BT, Just RJ, Castell DO. Persistent acid secretion during omeprazole therapy: a study of gastric acid profiles in patients demonstrating failure of omeprazole therapy. Am J Gastroenterol 1996; 91: 1527 31.
  • 35
    Katzka DA & Castell DO. Successful elimination of reflux symptoms does not insure adequate control of acid reflux in patients with Barrett's esophagus. Am J Gastroenterol 1994; 89: 989 91.
  • 36
    Katz PO, Anderson C, Khoury R, Castell DO. Gastro-oesopha- geal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors. Aliment Pharmacol Ther 1998; 12: 1231 4.
  • 37
    Khoury RM, Katz PO, Hammond R, Castell DO. Bedtime ranitidine does not eliminate the need for a second daily dose of omeprazole to suppress nocturnal gastric pH. Aliment Pharmacol Ther 1999; 13: 675 8.
  • 38
    Peters FTM, Kuipers EJ, Ganesh S, et al. The influence of H. pylori on oesophageal acid exposure in GERD during acid suppressive therapy. Aliment Pharmacol Ther 1999; 13: 921 6.
  • 39
    Loughney T, Maydonovitch CL, Wong RKH. Esophageal manometry and ambulatory 24-hour pH monitoring in patients with short and long segment Barrett's esophagus. Am J Gastroenterol 1998; 93: 916 9.